Key Highlights
- 245.17% is the three-month raw gain for Moderna (NASDAQ:MRNA) in the relative strength table, against 244.20% in its single article, a 0.97 point conflict (own arithmetic). The shares fell 10.23% to USD 212.30 on October 16, 2026, for a USD 84.76 billion market capitalisation.
- 207.60% is the three-month raw gain for Iovance (NASDAQ:IOVA), against 206.72% in its single article. Raised 2026 revenue guidance of USD 410 to 420 million, announced September 29, 2026, supports the trend, and the shares fell 5.40% to USD 13.93 on October 16, 2026.
- 166.40% is the three-month raw gain for Avita Medical (NASDAQ:RCEL), against 166.20% in its single article. Guidance of USD 86 to 89 million and a fourth quarter 2026 breakeven target sit against USD 11.1 million of cash and a USD 46.7 million loan facility.
- 113.32% is the three-month raw gain for Kodiak Sciences (NASDAQ:KOD), against 111.54% in its single article, yet its one-month relative strength of 160.23 is the highest of the four. DAYBREAK Phase 3 data on September 28, 2026 drove the move.
Moderna (NASDAQ:MRNA)
The market is paying for cancer revenue the company does not yet earn. Moderna (NASDAQ:MRNA) holds the top three-month relative strength at 241.19 (the 245.17% raw gain less a 3.98% benchmark gain, own arithmetic). The catalyst was the August 19, 2026 announcement that intismeran autogene with Keytruda met its primary recurrence-free survival goal in resected melanoma, followed by Nasdaq-100 inclusion before the October 9 open. Citi cut the stock to sell on September 30, 2026 with a USD 80 target and estimates USD 26 billion of annual cancer sales would be needed to support USD 200. Implied trailing sales are USD 2.10 billion at a price to sales ratio of 40.4 (own arithmetic). Consensus is Hold with an average target of USD 78.17. No company-specific catalyst was identified for the October 16 decline. What separates it: the largest market value and the largest gap to analyst targets. So what: index demand is a one-time event, and JPMorgan (underweight, USD 77) and Redburn (sell, USD 81) also sit far below the USD 212.30 quote, so overall survival data and manufacturing scale-up carry the next test.
Iovance (NASDAQ:IOVA)
This is the only name of the four whose guidance is already rising. Iovance (NASDAQ:IOVA) lifted 2026 revenue guidance on September 29, 2026 to USD 410 to 420 million from USD 350 to 370 million, a 15.3% rise at the midpoint (own arithmetic), and the shares rose 32.7% that day. Second quarter revenue grew 65.7% on August 6, 2026, with a 56% gross margin on Amtagvi. At a USD 6.31 billion capitalisation the stock trades at 15.2 times the USD 415 million guidance midpoint (own arithmetic), against a trailing net loss of USD 391 million. Short interest is 15.5% of float, which can amplify reversals. The average analyst target of USD 13.20 sits below the USD 13.93 quote. What separates it: reported sales growth, not a pending trial. So what: execution must continue past 2026. Oral SARATOGA data is expected in late October, and results are estimated for November 5, 2026.
Avita Medical (NASDAQ:RCEL)
The rally rests on a company growing and cutting costs while its cash cushion thins. Avita Medical (NASDAQ:RCEL) reported record second quarter revenue of USD 21.7 million on August 6, 2026, up 18%, with an 81.9% gross margin and a net loss narrowed to USD 7.7 million. Net cash use fell to USD 3.2 million from USD 9.9 million, and management expects cash flow breakeven in the fourth quarter. Cash and marketable securities were USD 11.1 million on June 30, 2026, which covers 3.5 quarters at the second quarter burn (own arithmetic). The loan facility was USD 46.7 million against a stockholders' deficit of USD 27.8 million. Guidance needs second half quarterly revenue of USD 22.6 to 24.1 million, 4% to 11% above the second quarter (own arithmetic). What separates it: the smallest market value, USD 409 million, and the thinnest balance sheet. So what: a miss would endanger both breakeven and a USD 10 million loan tranche that needs trailing twelve-month revenue of USD 85 million in any month before March 31, 2027. No company-specific catalyst was identified for the 1.34% decline on October 16, 2026.
Kodiak Sciences (NASDAQ:KOD)
The market now prices regulatory approval for a company with no approved product. Kodiak Sciences (NASDAQ:KOD) rose 178% intraday on September 28, 2026 after DAYBREAK Phase 3 results in wet age-related macular degeneration, where the company said Zenkuda matched or exceeded Eylea. It plans a multi-indication biologics license application in the fourth quarter, built on five positive Phase 3 studies. At USD 85.99 the stock is 79.7% above its prior 52-week high of USD 47.84 and 17.3% below the new USD 103.93 high (own arithmetic). Cash was USD 125.9 million on June 30, 2026, equal to 2.3% of the USD 5.40 billion market capitalisation (own arithmetic), and the company expects it to fund operations into 2027. What separates it: a newer, single-event rally with the lowest three-month gain and the highest price to book, 88.4. So what: financing is the central mechanical question, because an illustrative USD 500 million raise would equal 9.3% of market capitalisation (hypothetical arithmetic, not an announced offering). PEAK data is due in late 2026, and the third quarter report date was not announced.
Where Things Stand
Moderna (NASDAQ:MRNA) leads biotech relative strength, ahead of Iovance, Avita Medical and Kodiak Sciences, though leadership is not valuation support. Subtracting the 3.98% implied benchmark gain gives 241.19 for MRNA, 203.62 for IOVA, 162.42 for RCEL and 109.34 for KOD (own arithmetic), while the one-month order reverses, with KOD at 160.23 and MRNA at 44.97. Each name is priced beyond current financials: MRNA at 40.4 times sales, IOVA at 15.2 times guided sales, RCEL on a breakeven target and KOD on a pending filing. Dated catalysts are the SARATOGA data in late October, the Kodiak BLA in the fourth quarter and Iovance results estimated for November 5, 2026.






Please wait processing your request...